Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesMechanical prophylaxis to prevent venous thromboembolism in surgical patients: A prospective trial evaluating compliance
Journal of Critical Care, 06/12/09
Bockheim HM et al. - Compliance with mechanical prophylaxis is suboptimal particularly in non-ICU patients. Strategies to improve compliance or alternative prophylaxis should be considered in those patients.
Related Articles
Factors That Predict Risk of Thrombosis in Relatives of Patients With Unprovoked Venous Thromboembolism
Chest, 10/08/09
Relevance Score: 69%
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
Circulation, 11/04/09
Relevance Score: 68%
Hematocrit and risk of venous thromboembolism in a general population. The Tromso Study
Haematologica, 10/21/09
Relevance Score: 68%
Risk factors and underlying mechanisms for venous stasis syndrome: a population-based case–control study
Vascular Medicine, 10/13/09
Relevance Score: 68%
Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER)
Annals of Oncology, 10/20/09
Relevance Score: 67%
Today in CV/Thromboembolic...keeping you current
Receive free subspecialty "5-minute updates" via email
The clinical course of pulmonary embolism patients anticoagulated for 1 year: results of a prospective, observational, cohort study
Journal of Thrombosis and Haemostasis, 12/18/09
Volumetric or time-based capnography for excluding pulmonary embolism in outpatients
Journal of Thrombosis and Haemostasis, 12/18/09
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
Rheumatology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor